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Chloralose (alpha-chloralose) is a poisonous substance currently used as a rodenticide or avicide. 
It has primarily been used in Europe since 1893 as a human and veterinary hypnotic agent. 
Chloralose is a central nervous system depressant also acting as a stimulant on spinal reflexes. In 
the present case, a 24-year-old man was found dead in his bedroom near vomit residues. Several 
items were seized from the scene, including an empty bottle of Murex 50 g (a-chloralose), sold in 
Italy as rodenticide. Postmortem examination revealed no evidence of natural disease or trauma. 
Heart blood, urine, gastric contents, vitreous humour, brain, bile and liver were collected and 
submitted for toxicological analysis. Several extraction procedures and a specific liquid 
chromatography–tandem mass spectrometry protocol were purposely developed and validated. 
Chloralose was found in blood at a concentration of 65.1 mg/L and high levels were also detected 
in the gastric contents, confirming its ingestion shortly before the man’s death. The distribution of 
chloralose in the body was evaluated by analyzing urine, vitreous humour, brain, bile and liver 
specimens. Quantitation of chloralose in several body fluids and tissues adds new data about the 

















Chloralose (alpha-chloralose) is a condensation product of chloral hydrate and glucose. It has 
been used primarily in Europe since 1893 as a human and veterinary hypnotic agent and as 
avicide and rodenticide for control of birds and rodents. In humans, chloralose has both a 
depressive effect on the central nervous system, producing sedation and anesthesia, and a 
stimulant effect on spinal reflexes, producing spontaneous myoclonic movements or generalized 
convulsions (1–3). Chloralose is no longer used in medical practice, but it has been available until 
recently as 75–300 mg oral and rectal dosage forms as anesthetic for human administration (4). 
Adverse reactions associated with chloralose overdosage include tachycardia, ataxia potentially 
progressing to prostration and coma, hypothermia or hyperthermia, rhabdomyolysis, miosis and 
respiratory depression (5–7). The oral toxic dose of chloralose is approximately 1 g in adults and 
20 mg/kg in infants (8). Chloralose is converted to chloral hydrate by hepatic metabolism, then 
transformed by further reduction to trichloroethanol, which is then oxidized to trichloroacetic acid or 
glucuronidated to urochloralic acid (4). The presence of these metabolites was not confirmed in 




A 24-year-old man was found unconscious in his bedroom shortly after vomiting. The family called 
the medical rescue, but after 30 min of resuscitation efforts, he was pronounced dead. The family 
members reported that he had been in treatment for depression since 2007 after a suicide attempt. 
Two weeks before his death, he had allegedly started taking mesterolone tablets, typically used to 
increase muscle mass. Several packages of pharmaceuticals were found in his room. Specifically, 
the police seized one opened box of Tavor (lorazepam) containing seven tablets, one opened box 
of Largactil (chlorpromazine) containing four tablets, two boxes of Pantoprazolo Mylan Generics 
(pantoprazole), one opened box of Proviron (mesterolone) containing 16 tablets and one empty 
bottle of Murex 50 g (chloralose), sold in Italy as rodenticide. Furthermore, several packages of 
nutritional supplements were also seized, including creatine, amino acids and proteins. The death 
was reported to the Public Prosecutor who took jurisdiction of the case. At the autopsy, the body 
appeared wellnourished and the internal examination presented no evidence of natural disease or 
trauma to account for his death. All the organs were macroscopically normal. General pulmonary 
edema and multi-visceral congestion were found. Hence, our laboratory was asked to execute the  
inherent toxicological analyses in order to determine whether a possible massive drug 
consumption could be taken into account as the cause of the death. The specimens sampled 





Alpha-chloralose, coumatetralyl, sodium hydrogen carbonate (NaHCO3), sodium carbonate 
(Na2CO3), sodium phosphate dibasic dehydrate (Na2HPO4 † 2H2O), potassium phosphate 
monobasic (KH2PO4), methanol, formic acid, acetonitrile, methyl t-butyl ether (MTBE), acetic acid 
( purity _ 99.7%), sodium acetate (CH3COONa), ammonium acetate (CH3COONH4) and b-
glucuronidase (from Escherichia coli) were purchased from Sigma–Aldrich (Milan, Italy). b-
Glucuronidase/arilsulfatase (from Helix pomatia) was obtained from Roche Diagnostic (Milan, 
Italy). Chloroform was purchased from Lab-Scan/Analytical Sciences (Dublin, Ireland). All solutions 
and buffers were prepared using deionized water obtained from Milli-Q system (Millipore, Billerica, 
MA). Acetate buffer 0.1M was prepared by dissolving 17.12 g of CH3COONa and 6.4 mL of acetic 
acid in 1 L of water. Phosphate buffer was prepared by dissolving 4.63 g of KH2PO4 and 11.75 g 
of Na2HPO4 † H2O in 1 L of water, whereas carbonate buffer was prepared by dissolving 2.12 g of 
Na2CO3 and 6.72 g of NaHCO3 in 1 L of water. 
 
Sample preparation 
For general screening analysis, 2 mL (or 1 g) of samples were extracted under alkaline conditions 
(pH 9.6) by adding 2 mL of a 0.1M carbonate buffer and then 10 mL of MTBE. After shaking the 
mixture in a multimixer for 10 min, the organic layer was separated and then dried under a gentle 
flow of nitrogen. The resulting residue was reconstituted with 50 mL of methanol. Finally, a 1-mL 
aliquot was injected (split ratio of 10:1) into the gas chromatography–mass spectrometry (GC–MS) 
system. Before liquid–liquid extraction, urine samples were buffered at pH 7.4 with 2 mL of a 0.1M 
phosphate buffer and deconjugated by adding 30 mL of b-glucuronidase before incubating the 
mixture at 558C for 1 h. For chloralose quantitation, coumatetralyl was chosen as the internal 
standard (1 mg/mL final concentration). Three extraction procedures were developed for the 
detection and quantitation of chloralose in blood, urine and tissues that are briefly reported in Table 
I. Ten microliters of the final extract was injected into the liquid chromatography–tandem mass 
spectrometry (LC–MS-MS) instrument. 
 
Apparatus and methods 
Preliminary screening analyses for amphetamines, tricyclic antidepressants, barbiturates, 
benzodiazepines, cannabinoids, methadone, cocaine and opiates were performed by enzyme 
multiplied immunoassay technique (EMIT; Abbott Laboratories, IL), while the ethanol concentration 
in blood, urine and gastric content was determined by a headspace-gas chromatography–mass 
spectrometry (HS-GC–MS) method. Screening analysis for unknown substances was performed 
using a 6890N gas chromatograph (Agilent Technologies, Milan, Italy) equipped with a 17-m fused-
silica capillary column (J&W Scientific HP-5) of 0.2-mm inner diameter and 0.33-mm film thickness, 
for GC separation. Helium was employed as the carrier gas at a constant pressure of 23.24 psi. 
The gas chromatograph oven temperature was set at 908C for 1 min and then raised to 1808C 
with a 308C/min heating rate. The oven temperature was maintained at 1808C for 7 min and then 
raised to 3158C with a 158C/min heating rate. The gas chromatograph injector and transfer line 
were maintained at 2808C. Full scan spectra in the interval 50–500 amu were acquired using a 
5975 inert mass-selective detector (Agilent) operating in the EI mode at 70 eV. For chloralose 
confirmation analyses, a specific LC–MS-MS procedure was developed and validated. 
Chromatographic separation was performed using an Agilent 1100 series liquid chromatograph 
equipped with a Merck LiChroCart Purospher STAR-RP C18 column (4.6 _ 150 mm, 5 mm) 
protected by a guard column. The elution solvents were ammonium acetate 10 mM solution 
(component A) and methanol (component B). The mobile phase eluted under the following linear 
gradient conditions: (A:B; v:v) from 60:40 to 10:90 in 18 min, with 7 min for re-equilibration. Each 
chromatographic separation was run at a flow rate of 500 mL/min. Detection was carried out by an 
Applied Biosystems API 3200 triple quadrupole mass spectrometer (ABSCIEX, Foster City, CA) 
equipped with turbo ion spray source, operating in the negative ionization mode. Optimal results 
were obtained using a source block temperature of 3508C. Data were recorded in the selected 
reaction monitoring (SRM) mode. To establish appropriate SRM conditions, the analyte and the 
internal standard (IS) were individually infused into the electrospray ionization (ESI) capillary and 
the cone voltage (CV) was adjusted to maximize the intensity of the deprotonated molecular 
species. Collision energy voltage (CE) was selected to preserve approximately 10% of precursor 
ion. Nitrogen was employed as the collision gas. Precursor ion and the corresponding product ions 
for chloralose and IS are presented in Table II. Qualitative and quantitative analysis for 
chlorpromazine, mesterolone (17b-hydroxy-1a-methyl-5a-androstan-3-one), mesterolone 
metabolites (met 1: 3a-hydroxy-1a-methyl-5a-androstan-17-one; met 2: 1a-methyl-5a-androstan-
3a,17b-diol) and lorazepam were performed in blood and urine specimens by means of analytical 
methods used in our laboratory and described elsewhere (10, 11). 
 
Validation of the LC–MS-MS confirmation methods for chloralose quantitation 
The method was validated by investigating the following parameters: selectivity, linearity, 
identification and quantitation limits (limit of detection, LOD, and limit of quantitation, LOQ), 
precision, accuracy and recovery. Matrix effect phenomena were also evaluated (12, 13). Blood, 
urine and liver were chosen as the target matrices for method validation. The linear calibration 
models were checked by analyzing (three replicates) blank samples (blood, urine and liver) spiked 
with chloralose standard solution at final concentrations of 0, 0.75, 1, 5, 10, 50, 100, 150 and 200 
mg/L (or mg/kg). Whenever the effective  drug concentration exceeded the calibration range, the 
samples were diluted to fit the quantitation interval considered in the curve. Dilution integrity was 
evaluated spiking the matrix at concentration 1.5 times the highest calibration point (300 mg/L or 
mg/kg) and diluting them twice and ten times with blank matrix. These samples were analyzed 
along the calibration curve and the accuracy was considered satisfactory in the interval +15%. 
For each matrix, ten different blank samples were prepared as described in Table I to test the 
selectivity of the whole analytical procedure. The occurrence of possible interferences from 
endogenous substances was checked by monitoring the signal-to-noise ratio (S/N) for the 
chloralose SRM transitions at the expected retention time. Matrix effects were evaluated by 
comparing the signal obtained when the analyte was added to the matrix extract with the response 
obtained from a methanolic solution containing the analyte at the same concentration. LOD values 
were estimated as the analyte concentration whose response provided an S/N value equal to 3, as 
determined from the least abundant transition. LOD values were extrapolated from S/N recorded at 
the concentration of 0.375 mg/L or mg/kg, whereas the lowest calibration point was 0.75 mg/L. The 
calculated LOD was then experimentally confirmed by analyzing spiked samples at LOD 
concentration of chloralose. LOQ values were estimated as the analyte concentration whose 
response provided an S/N value equal to 10. LOQ generally corresponds to the lowest 
concentration that provides a useful signal along the calibration curve. Relative extraction 
recoveries were determined by comparing the responses of the extracted samples (five replicates 
for blood, urine and liver) initially spiked with the analytes at a final concentration of 10 and 100 
mg/L (or mg/kg) with the responses of blank samples in which chloralose was added at the same 
concentration after the extraction step. Within-batch precision (expressed as percent variation 
coefficient, CV%) and accuracy (expressed as bias percent), were assessed by extracting and 
analyzing, for each tested matrix, a series of five samples fortified at 10 and 100 mg/L (or mg/kg). 
 
Results and Discussion 
 
On the basis of the mass-spectrometric data, three diagnostic transitions for chloralose and one 
characteristic transition for the internal standard were acquired. The SRM chromatograms from 10 
negative samples of blood, urine and liver showed no interfering signals (i.e., S/N ratio lower than 
3) at the corresponding retention time for the three matrixes tested. This demonstrated the 
selectivity of the methods and that they are free from interferences from matrix components. The 
LODs for chloralose were estimated from the previously described calculations at 0.02 and 0.16 
mg/L in blood and urine, respectively, and 0.04 mg/kg in liver, resulting from S/N ratios of 60, 7 and 
26 in blood, urine and liver, respectively. Estimated LODs were experimentally confirmed by 
analyzing in triplicate a blank matrix sample (blood, urine and liver) spiked with chloralose at the 
LOD concentration. All the observed S/N ratios exceed the critical value of 3, as expected. The 
estimated LOQ values for chloralose were 0.06 and 0.54 mg/L in blood and urine, respectively, and 
0.14 mg/kg in liver. These values are smaller than the lowest calibration point, which was arbitrarily 
fixed at 0.75 mg/L in blood and urine and 0.75 mg/kg in liver. Calibration curves (eight points plus a 
zero sample) were generated by linear regression and exhibited squared correlation coefficients 
(R2) of 0.9915 (blood), 0.9953 (urine) and 0.9934 (liver). At 10 mg/L (or mg/kg) concentration, 
extraction recoveries were 103.3, 26.0 and 12.8% in blood, urine and liver, respectively, while at 
100 mg/L (or mg/kg), the extraction recoveries were 97.1, 35.2 and 18.6% in blood, urine and liver. 
The within-batch data on precision and accuracy are reported in Table III. The results show a 
satisfactory repeatability, because the CV% is lower than 10% for chloralose spiked in blood, urine 
and liver samples at both 10 and 100 mg/L (or mg/kg). In the three tested matrices, the accuracy 
(expressed as percent bias) varies from þ1.1 to 29.2% and all experimental bias values were 
below the acceptable limit of +15% at 10 and 100 mg/L (or mg/kg) concentration. At the two tested 
concentrations, no significant matrix effects were found for chloralose in the different matrix (values 
between 21.6% and þ6.0%). However, to prevent matrix effects, possibly present when a specific 
matrix has to be analyzed, all calibrations and validation tests were conducted on the target 
matrices spiked with the analyte standard solution. All validation results are summarized in Table 
III.  In the real case reported, the presence of chloralose was confirmed in all specimens; all the 
toxicological results are reported in Table IV. Therapeutic levels for chloralose are not reported in 
literature. In four reported poisoning cases involving chloralose, the plasma concentrations ranged 
from 13.7 to 41.3 mg/L (mean 25.4 mg/L) (9), whereas in seven comatose patients, the drug was 
found at an average level of 50 mg/L (range, 6.8– 180 mg/L) (4). In three fatal cases due to 
massive ingestion of chloralose, postmortem peripheral blood concentrations were between 151 
and 410 mg/L (4, 14, 15). In the case presented here, the heart blood concentration of chloralose 
was 65.1 mg/L. The LC–MS-MS profile resulting from the detection of chloralose in blood and the 
profile of blank blood samples are shown in Figure 1. This concentration is lower than those 
previously reported, but it can be considered highly toxic. Indeed, the diagnosis of chloralose 
intoxication is frequently immediate, so that a rapid treatment can be carried out (i.e., gastric 
lavage, activated charcoal, sedation with benzodiazepines or mechanical ventilation), leading to 
complete recovery. The prolongation of a comatose state without an early emergency remedy can 
lead to acute respiratory failure resulting in cardiac arrest (3). Free and total chloralose were also 
identified in urine. Glucuronide conjugate exceeded the free parent drug by 7.3-fold. This finding 
confirms that chloralose is excreted primarily as the glucuronide metabolite, as previously reported 
(9, 16). Other analytical findings indicate the recent intake of lorazepam, chlorpromazine and 
mesterolone, consistent with scene investigation. Due to their low blood levels, their presence was 







This report presents a fatal case involving acute intoxication by alpha-chloralose. After preliminary 
GC–MS screening, a specific LC–MS-MS procedure was developed and validated to specifically 
and accurately detect the drug in various human fluids and tissues. The high concentration in the 
gastric content proved the recent massive ingestion of chloralose. Chloralose was measured in 
bile, liver, brain and vitreous humour, all of which showed a significant presence of the drug. 
However, vitreous humour was not a major site of alpha-chloralose deposition, as previously 
described in fatal cases involving an acute consumption of chloralose (15). Finally, the heart blood 
concentration was in the range considered to be highly toxic, although lower than that found in 
previous cases. In conclusion, the agreement between the postmortem examination and the 
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Table 1. Sample preparation procedures for the detection of chloralose in blood, urine and tissue specimens 
 Blood samples  Urine samples  Tissue samples (validated as liver) 
1. 300 µL blood + 15 µL IS  
(20 µg/mL solution) 
1. 300 µL urine + 15 µL IS  
(20 µg/mL solution) 
1. 2 g of tissue (homogenate) + 40 µL IS  
(40 µg/mL solution) 
2. Adding 1.5 mL of acetonitrile  
and mixing for 5 minutes 
2. Adding 40 µL of enzyme
#
  
and incubating for 1 h at 37°C 
2. Adding 10 mL of Acetate buffer  
(0.1 M at pH 5) and mixing for 5 minutes 
3. Centrifuging at 3000 rpm for 5 minutes  
and taking the supernatant layer 
3. Adding 1.5 mL of chloroform  
and mixing for 5 minutes 
3. Centrifuging at 3000 rpm for 5 minutes  
and taking the aqueous layer 
4. Drying the solvent under nitrogen at 50°C 4. Centrifuging at 3000 rpm for 5 minutes  
and taking the organic layer   
4. Adding 10 mL of chloroform  
and mixing for 5 minutes 
5. Reconstituting the dry residue  
with 300 µL of mobile phase
*
 
5. Drying the solvent under nitrogen at 50°C 5. Centrifuging at 3000 rpm for 5 minutes  
and taking 1 mL of organic solvent 
  6. Reconstituting the dry residue  
with 300 µL of mobile phase
*
 
6. Drying the solvent under nitrogen at 50°C 





mobile phase = ammonium acetate 10 mM:methanol 60:40 v/v 
# 
-glucuronidase/arilsulfatase from Helix pomatia  
 
Table 2. Mass Chromatographic Conditions for Chloralose and Coumatetralyl (IS) 
Compound RT (min) SRM transitions (m/z) CV* (V) CE* (V) CXP* (V) 
  307.2 71.0 40 38 2 
Chloralose 9.89 307.2 100.8 40 23 2 
  307.2 85.0 40 32 1 
Coumatetralyl 11.80 291.0 141.2 65 37 4 
*CV = cone voltage, CE = collision energy and CXP = Collision Cell Exit Potential. 
 
#
 calculated LOQ 
*all concentrations are expressed as mg/kg 
 
















Precision (CV%) Accuracy (bias%) Recovery (%) Matrix effect (%) 
10 mg/L 100 mg/L 10 mg/L 100 mg/L 10 mg/L 100 mg/L 10 mg/L 100 mg/L 
Blood  0.75 200 0.9915 0.02 0.06 8.7 5.2 +1.7 +1.1 103.3 97.1 0.7 +1.4 
Urine  0.75 200 0.9953 0.16 0.54 6.4 4.6 9.2 7.6 26.0 35.2 1.6 +1.5 
Liver* 0.75 200 0.9934 0.04 0.14 5.6 5.0 +4.7 +3.2 12.8 18.6 +6.0 +4.8 





Chlorpromazine: 0.19 mg/L 




Lorazepam: 1.08 mg/L 
Mesterolone: 2.22 mg/L 
Mesterolone met 1: 11.9 mg/L 
Mesterolone met 2: 0.69 mg/L 
Bile 66.6 - 
Gastric Content 6750 - 
Vitreous Humour  24.7 - 
Liver 62.1 (mg/kg) - 




Figure 1. Comparison between the extracted ion chromatogram resulting from the detection of chloralose in 
the victim’s blood (a) and a blank blood sample (b).  
 
 
 
 
 
 
